A 1,740% share price surge in a single year would usually signal that most of the upside in a biotech stock has already been realized. Yet for French biopharmaceutical company Abivax (ABVX), some market analysts believe the rally may not be over, pointing to the potential for a further gain of up to 72% this year.
That bullish view rests on two main pillars: a highly differentiated late-stage ulcerative colitis therapy and market speculation about a possible big-ticket acquisition by a global pharmaceutical giant.
Abivax’s explosive performance last year was driven primarily by obefazimod, its core investigational drug, which achieved significant milestones in clinical development.
The therapy targets ulcerative colitis (UC), a chronic inflammatory bowel disease representing a sizeable and competitive global market. Unlike many current standard treatments that work by suppressing the immune system to control inflammation—often at the cost of raising the risk of infections and other side effects—obefazimod is being developed to take a more differentiated approach.
Clinical data to date indicate that obefazimod can induce clinical remission without broadly weakening the overall immune system. In its phase 3 trials, nearly half of the patients enrolled were classified as difficult-to-treat, having shown inadequate response to prior therapies. This suggests the drug could potentially address a broader patient population than many existing options, giving it substantial commercial potential if successfully approved and commercialized.
Beyond the clinical value of obefazimod, the more immediate driver of market excitement is speculation around a potential major transaction. According to reports, Eli Lilly is considering acquiring Abivax in a deal that could value the French company at around EUR 15 billion. Based on Abivax’s current market capitalization of approximately EUR 8.74 billion, such a transaction would imply an upside of about 72% from present levels.
For Eli Lilly, acquiring Abivax would provide instant access to a promising immunology asset, strengthening its competitive position in autoimmune and inflammatory diseases. The addition of obefazimod could enhance Lilly’s pipeline and broaden its portfolio in a strategically important therapeutic area. Even if Lilly does not ultimately proceed with an offer, market observers note that the strong clinical profile of obefazimod is likely to keep Abivax on the radar of other large pharmaceutical players. This ongoing takeover expectation may continue to support the company’s valuation and perceived upside, at least in the near term.
These two factors together underpin the view that Abivax’s rally may have further room to run, despite last year’s extraordinary performance.
However, the risks are equally significant. Obefazimod still faces the usual uncertainties inherent in drug development and commercialization. On the path to regulatory approval and market launch, the program could encounter clinical setbacks or regulatory hurdles, any of which might materially affect the company’s valuation.
In addition, Abivax’s current share price already embeds a substantial amount of optimism about both the clinical trajectory of obefazimod and the likelihood—or terms—of any potential takeover. If the much-discussed acquisition scenario fails to materialize, the stock could experience a sharp correction as expectations are repriced.
Against this backdrop, Abivax stands out as a classic high-risk, high-reward biotech investment. The stock is not well-suited to risk-averse investors or those uncomfortable with the volatility and binary outcomes typical of late-stage biotech assets. However, for investors who can tolerate significant price swings, and have a deep understanding of biotechnology and clinical development risks.
